Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Insigna Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which represents the total active prosecution volume. This action indicates a focused effort on a specific patent application within the biotech sector. For a practitioner, this limited volume allows for a highly specialized response strategy.
The company's filings are being reviewed by a distinct examiner in a single art unit. This concentration suggests that the technical subject matter is highly specialized or limited in scope. COPPINS, JANET L is the busiest examiner assigned to the portfolio. The involvement of a single art unit means that the prosecution is subject to the specific internal policies of that administrative group.
COPPINS, JANET L is responsible for 1 busiest examiner pending office action. Since this matches the total count of pending actions, the individual review process of COPPINS, JANET L will significantly impact the portfolio's immediate progress. Practitioners should monitor the specific requirements of this examiner to navigate the prosecution effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18099654 | ANIMAL STERILIZATION BY ESTROGENIC COMPOUNDS | COPPINS, JANET L | 28d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18099654 | ANIMAL STERILIZATION BY ESTROGENIC COMPOUNDS | COPPINS, JANET L | 1628 | §112Other | Non-Final OA | 28d | Pending | Jan 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial